ZimVie (NASDAQ:ZIMV - Get Free Report) is expected to announce its earnings results after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.25 per share and revenue of $113.67 million for the quarter. Investors that are interested in participating in the company's conference call can do so using this link.
ZimVie Stock Performance
Shares of NASDAQ:ZIMV traded down $0.01 during trading on Friday, reaching $13.31. The company had a trading volume of 185,010 shares, compared to its average volume of 106,811. The firm has a market capitalization of $367.36 million, a price-to-earnings ratio of -1.02 and a beta of 2.10. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.94 and a quick ratio of 1.38. The stock's fifty day moving average price is $13.80 and its 200 day moving average price is $14.90. ZimVie has a fifty-two week low of $12.84 and a fifty-two week high of $22.40.
ZimVie Company Profile
(
Get Free Report)
ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.
Further Reading
Before you consider ZimVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ZimVie wasn't on the list.
While ZimVie currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
